Drugs

Jun 18, 2025, 09:15

Raul Cordoba: Nivolumab-AVD vs Brentuximab Vedotin–AVD in Advanced-Stage Classic Hodgkin Lymphoma

Raul Cordoba, Chair of Community Stakeholder Committee at European Hematology Association (EHA), shared a post on X:

“Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826 |⁩ Journal of Clinical Oncology”

Title: Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826

Authors: Sarah C. Rutherford, Hongli Li, Alex F. Herrera, Michael LeBlanc, Sairah Ahmed, Kelly Davison, Susan K. Parsons, Joseph M. Unger, Anamarija M. Perry, Carla Casulo, Nancy L. Bartlett, Joseph M. Tuscano, Brian T. Hess, Pallawi Torka, Pankaj Kumar, Ryan Jacobs, Joo Y. Song, Sharon M. Castellino, Brad Kahl, John P. Leonard, Sonali M. Smith, Jonathan W. Friedberg, Andrew M. Evens

Read Full Article.

Nivolumab-AVD Nivolumab-AVD

More posts featuring Raul Cordoba on OncoDaily

Alex F. Herrera Anamarija M. Perry Andrew M. Evens Brad Kahl Brentuximab Vedotin–AVD Brian T. Hess cancer Carla Casulo Hongli Li John P. Leonard Jonathan W. Friedberg Joo Y. Song Joseph M. Tuscano Joseph M. Unger Journal of Clinical Oncology Kelly Davison Michael LeBlanc Nancy L Bartlett Nivolumab-AVD OncoDaily Oncology Pallawi Torka Pankaj Kumar Raul Cordoba Ryan Jacobs Sairah Ahmed Sarah C. Rutherford Sharon M. Castellino Sonali M. Smith Susan K. Parsons

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth